Iron Path Capital’s VION Biosciences closes acquisition of Prolytix
Published on September 9, 2026
Prolytix provides regulated bioanalytical and CMC services, research reagents, and custom sample collection products to biopharma and diagnostics customers.
The post Iron Path Capital’s VION Biosciences closes acquisition of Prolytix appeared first on PE Hub.
